Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$132.06 USD

132.06
4,690,585

+1.13 (0.86%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $132.75 +0.69 (0.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.

Zacks Equity Research

Orthofix (OFIX) Launches Limb Lengthening System in US & UK

by Zacks Equity Research

With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.

Zacks Equity Research

Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.

Zacks Equity Research

Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio

by Zacks Equity Research

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

Zacks Equity Research

LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.

Zacks Equity Research

Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat

by Zacks Equity Research

Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.

Zacks Equity Research

HEXO Soars: Stock Adds 7.9% in Session

by Zacks Equity Research

HEXO saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Here's Why Abbott (ABT) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.

Zacks Equity Research

QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve

by Zacks Equity Research

QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.

Zacks Equity Research

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Zacks Equity Research

Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe

by Zacks Equity Research

Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.

Zacks Equity Research

Boston Scientific (BSX) Hurt by Product Recall, Conversion

by Zacks Equity Research

Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.

Zacks Equity Research

Hill-Rom's (HRC) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Hill-Rom's (HRC) first-quarter fiscal 2021 revenue climbed 8.2% year over year to $741.1 million.

Zacks Equity Research

Zimmer Biomet (ZBH) Beats on Q4 Earnings, to Rejig Portfolio

by Zacks Equity Research

Zimmer Biomet (ZBH) states that continued pressure from the COVID-19 pandemic slowed the recovery of elective procedures in the fourth quarter.

Zacks Equity Research

Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results reflect strong segmental performance.

Zacks Equity Research

Cardiovascular Systems (CSII) Posts Break-Even Earnings in Q2

by Zacks Equity Research

Cardiovascular Systems (CSII) registers dismal revenues despite gradual recovery in business amid the pandemic.

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q1

by Zacks Equity Research

Each of Becton Dickinson's (BDX) core units witnesses strong revenue growth in the fiscal first quarter.

Zacks Equity Research

Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ABT) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Quest Diagnostics (DGX) Q4 Earnings Top, Base Recovery Slows

by Zacks Equity Research

Quest Diagnostics' (DGX) first-half 2021 outlook looks impressive thanks to strong revenue growth expectations.

Zacks Equity Research

Change Healthcare (CHNG) Q3 Earnings Top Estimates, Up Y/Y

by Zacks Equity Research

Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance in the Network Solutions segment.

Zacks Equity Research

Baxter (BAX) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) fourth-quarter results reflect robust performance across five of its business units.

Zacks Equity Research

AmerisourceBergen (ABC) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.

Zacks Equity Research

Align Technology (ALGN) Beats on Q4 Earnings, Margins Up

by Zacks Equity Research

Align Technology's (ALGN) segments report solid sales across geographies despite the pandemic-led business challenges.

Zacks Equity Research

Phibro (PAHC) Q2 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) second-quarter revenue declined 3.7% year over year to $206.1 million and gross profit improved 33%.